ZILRIENSE Trademark

Trademark Overview

On Friday, July 21, 2017, a trademark application was filed for ZILRIENSE with the United States Patent and Trademark Office. The USPTO has given the ZILRIENSE trademark a serial number of 87537787. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, January 10, 2022. This trademark is owned by Bristol-Myers Squibb Company. The ZILRIENSE trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for human use for the treatment and prevention of obesity, diabetes, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection - all of the foregoing excluding pharmaceuticalpreparations and substances for the treatment and/or management of sleep disorders, namely, narcolepsy; pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer - all of the foregoing excluding pharmaceutical preparations and substances for the treatment and/or management of sleep disorders, namely, narcolepsy
zilriense

General Information

Serial Number87537787
Word MarkZILRIENSE
Filing DateFriday, July 21, 2017
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, January 10, 2022
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, May 29, 2018

Trademark Statements

Goods and ServicesPharmaceutical preparations for human use for the treatment and prevention of obesity, diabetes, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection - all of the foregoing excluding pharmaceuticalpreparations and substances for the treatment and/or management of sleep disorders, namely, narcolepsy; pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer - all of the foregoing excluding pharmaceutical preparations and substances for the treatment and/or management of sleep disorders, namely, narcolepsy

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, July 27, 2017
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameBristol-Myers Squibb Company
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressNew York, NY 10016
Party NameBristol-Myers Squibb Company
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew York, NY 10154

Trademark Events

Event DateEvent Description
Monday, January 10, 2022ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, January 10, 2022ABANDONMENT - NO USE STATEMENT FILED
Wednesday, June 9, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, June 8, 2021EXTENSION 5 GRANTED
Wednesday, June 2, 2021EXTENSION 5 FILED
Tuesday, June 8, 2021CASE ASSIGNED TO INTENT TO USE PARALEGAL
Wednesday, June 2, 2021TEAS EXTENSION RECEIVED
Tuesday, December 8, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, December 4, 2020EXTENSION 4 GRANTED
Friday, December 4, 2020EXTENSION 4 FILED
Friday, December 4, 2020TEAS EXTENSION RECEIVED
Saturday, June 6, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, June 4, 2020EXTENSION 3 GRANTED
Thursday, June 4, 2020EXTENSION 3 FILED
Thursday, June 4, 2020TEAS EXTENSION RECEIVED
Friday, December 6, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, December 4, 2019EXTENSION 2 GRANTED
Wednesday, December 4, 2019EXTENSION 2 FILED
Wednesday, December 4, 2019TEAS EXTENSION RECEIVED
Thursday, June 6, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, June 4, 2019EXTENSION 1 GRANTED
Tuesday, June 4, 2019EXTENSION 1 FILED
Tuesday, June 4, 2019TEAS EXTENSION RECEIVED
Tuesday, December 4, 2018NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Wednesday, October 24, 2018CHANGES/CORRECTIONS AFTER PUB APPROVAL ENTERED
Wednesday, October 24, 2018ASSIGNED TO PETITION STAFF
Monday, October 8, 2018APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Monday, October 8, 2018TEAS CHANGE OF OWNER ADDRESS RECEIVED
Sunday, October 7, 2018EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
Friday, September 21, 2018TEAS POST PUBLICATION AMENDMENT RECEIVED
Thursday, June 28, 2018EXTENSION OF TIME TO OPPOSE RECEIVED
Tuesday, May 29, 2018OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, May 29, 2018PUBLISHED FOR OPPOSITION
Wednesday, May 9, 2018NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Thursday, April 26, 2018APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, April 25, 2018TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, April 25, 2018CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, April 25, 2018ASSIGNED TO LIE
Tuesday, April 17, 2018TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, October 17, 2017NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, October 17, 2017NON-FINAL ACTION E-MAILED
Tuesday, October 17, 2017NON-FINAL ACTION WRITTEN
Tuesday, October 10, 2017ASSIGNED TO EXAMINER
Thursday, July 27, 2017NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Tuesday, July 25, 2017NEW APPLICATION ENTERED IN TRAM

Related Keywords

zilriense diseases disorders treatment pharmaceutical namely preparations substances narcolepsy anti human